Introduction
Methods
Design
Samples
Data collection
HRQoL measure
Statistical analysis
Descriptive analysis
Survival analysis
Models with SF-36 scores
Models with QLQ C-30 scores
Results
Patient characteristics
SF-36 (n = 230) | QLQ C-30 (n = 230) | |||
---|---|---|---|---|
Mean ± SD | n [%] | Mean ± SD | n [%] | |
Age | 60.2 ± 10.7 | 60.1 ± 10.7 | ||
Sex: | ||||
- Men | 186 [80.9] | 184 [80.0] | ||
- Women | 44 [19.1] | 46 [20.0] | ||
Stage of cancer | ||||
- I or II | 49 [21.3] | 48 [20.9] | ||
- III | 136 [59.1] | 141 [61.3] | ||
- IV | 45 [19.6] | 41 [17.8] | ||
Treatments before the HRQoL measurement | ||||
- Chemotherapy only | 133 [57.8) | 132 [57.4] | ||
- Radiotherapy only or with chemotherapy | 26 [11.3] | 24 [10.4] | ||
- Surgery alone or surgery and (radiotherapy or chemotherapy) | 71 [30.9] | 74 [32.2] | ||
Education level | ||||
- Primary | 64 [28.7] | 64 [29.6] | ||
- Secondary | 144 [64.6] | 136 [63.0] | ||
- Post-secondary | 15 [6.7] | 16 [7.4] |
HRQoL scores 3 months after the diagnostic process
SF-36
N | Mean | SD* | Median | Q1 | Q3 | |
---|---|---|---|---|---|---|
Physical functioning
| 230 | 50.1 | 27.2 | 50 | 27.8 | 70 |
Physical role
| 229 | 17.9 | 32.2 | 0 | 0 | 25 |
Bodily pain
| 229 | 46.2 | 25 | 41 | 31 | 62 |
Mental health
| 228 | 52.5 | 21.6 | 52 | 36 | 68 |
Emotional functioning
| 226 | 24.6 | 38 | 0 | 0 | 33.3 |
Social functioning
| 230 | 55.5 | 28 | 50 | 37.5 | 75 |
Vitality
| 227 | 32.9 | 19.6 | 30 | 20 | 45 |
General health
| 230 | 39.5 | 19.3 | 37 | 25 | 52 |
PCS
| 225 | 34.8 | 8.4 | 34.7 | 28.2 | 40.9 |
MCS
| 225 | 37.2 | 11.3 | 35.7 | 28.9 | 45.1 |
QLQ C-30
N | Mean | SD* | Median | Q1 | Q3 | |
---|---|---|---|---|---|---|
Physical functioning
| 230 | 63.2 | 23.9 | 66.7 | 53.3 | 80 |
Role functioning
| 228 | 47.2 | 34.1 | 50 | 16.7 | 66.7 |
Cognitive functioning
| 230 | 74.6 | 25.9 | 83.3 | 66.7 | 100 |
Emotional functioning
| 230 | 58.6 | 28.2 | 66.7 | 33.3 | 83.3 |
Social functioning
| 229 | 55.5 | 33.7 | 66.7 | 33.3 | 83.3 |
Fatigue
| 230 | 59.7 | 27.7 | 55.6 | 33.3 | 77.8 |
Pain
| 230 | 43.5 | 33.5 | 33.3 | 16.7 | 66.7 |
Nausea and vomitting
| 230 | 20.6 | 29.1 | 0 | 0 | 33.3 |
Insomnia
| 229 | 44.3 | 37.2 | 33.3 | 0 | 66.7 |
Constipation
| 228 | 28.1 | 33.9 | 33.3 | 0 | 33.3 |
Dyspnea
| 230 | 55.5 | 34.5 | 66.7 | 33.3 | 100 |
Diarrhea
| 229 | 11.5 | 24.2 | 0 | 0 | 0 |
Appetit loss
| 229 | 40 | 38.3 | 33.3 | 0 | 66.7 |
Global QoL
| 230 | 45.6 | 20.2 | 50 | 33.3 | 58.3 |
Prognostic value of HRQoL scores for patient survival
Bivariate analysis
Model without general health | ||||||
---|---|---|---|---|---|---|
Variables | Bivariate analysis | Multivariate analysis | ||||
HR | 95% CI | P | HR | 95% CI | p | |
HRQoL dimensions
| ||||||
Physical functioning ≥50 | 0.750 | 0.550 - 1.023 | 0.069 | 0.946 | 0.667 - 1.341 | 0.755 |
Physical role ≥50 | 0.651 | 0.428 - 0.991 | 0.046 | 0.576 | 0.326 - 1.016 | 0.057 |
Bodily pain ≥50 | 0.590 | 0.430 - 0.810 | 0.001 | 0.580 | 0.400 - 0.840 | 0.004 |
Emotional role ≥50 | 0.665 | 0.452 - 0.980 | 0.039 | 1.564 | 0.923 - 2.648 | 0.096 |
Social functioning ≥50 | 0.676 | 0.489 - 0.933 | 0.017 | 0.652 | 0.455 - 0.935 | 0.020 |
Mental health ≥50 | 0.792 | 0.581 - 1.081 | 0.142 | |||
Vitality ≥50 | 0.605 | 0.405 - 0.905 | 0.015 | 0.784 | 0.472 - 1.303 | 0.349 |
Patient characteristics
| ||||||
Age | 1.002 | 0.9 - 1.02 | 0.798 | 1.102 | 1.041 - 1.167 | <0.001 |
Sex: | ||||||
- Men | 1 | 1 | ||||
- Women | 0.859 | 0.575 - 1.285 | 0.460 | 0.556 | 0.351 - 0.881 | 0.012 |
Education level: | ||||||
- Primary | 1 | |||||
- Secondary | 0.820 | 0.581 - 1.157 | 0.259 | |||
- Post secondary | 0.739 | 0.374 - 1.461 | 0.384 | |||
Stage of cancer | ||||||
- Stage I - II | 1 | 1 | ||||
- Stage III | 1.670 | 1.088 - 2.565 | 0.019 | 21.388 | 3.460 - 132.187 | 0.001 |
- Stage IV | 3.341 | 2.025 - 5.511 | <0.001 | 633.964 | 21.799 - 18437.11 | <0.001 |
Treatment before the HRQoL measurement | ||||||
- Chemotherapy only | 1 | 1 | ||||
- Chemo and radiotherapy | 0.691 | 0.420 - 1.138 | 0.146 | 0.651 | 0.387 - 1.095 | 0.106 |
- Surgery alone or surgery and radiotherapy or chemotherapy | 0.219 | 0.144 - 0.333 | <0.001 | 0.186 | 0.115 - 0.300 | <0.001 |
Interaction
| ||||||
Age * Stage of cancer | 0.969 | 0.945 - 0.994 | 0.016 | 0.952 | 0.926 - 0.978 | <0.001 |
Model without global health | ||||||
---|---|---|---|---|---|---|
Bivariate analysis | Multivariate analysis | |||||
Variables | HR | 95% CI | p | HR | 95% CI | p |
Functioning domains (100 = good)
| ||||||
Physical functioning ≥50 | 0.612 | 0.431 - 0.869 | 0.006 | 0.787 | 0.506 - 1.226 | 0.289 |
Role functioning ≥50 | 0.640 | 0.469 - 0.874 | 0.005 | 0.907 | 0.573 - 1.437 | 0.677 |
Cognitive functioning ≥50 | 0.916 | 0.554 - 1.152 | 0.733 | |||
Social functioning ≥50 | 0.656 | 0.477 - 0.900 | 0.009 | 1.058 | 0.695 - 1.609 | 0.794 |
Emotional functioning ≥50 | 0.841 | 0.604 - 1.170 | 0.304 | |||
Symptom domains (100 = severe)
| ||||||
Pain <50 | 0.774 | 0.567 - 1.056 | 0.106 | |||
Fatigue <50 | 0.616 | 0.445 - 0.851 | 0.003 | 0.703 | 0.471 - 1.049 | 0.084 |
Sleep disturbance <50 | 0.876 | 0.641 - 1.197 | 0.406 | |||
Constipation <50 | 0.660 | 0.460 - 0.948 | 0.024 | 0.786 | 0.523 - 1.181 | 0.246 |
Nausea and vomiting <50 | 0.624 | 0.434 - 0.897 | 0.011 | 0.849 | 0.529 - 1.363 | 0.498 |
Apetite loss <50 | 0.628 | 0.457 - 0.863 | 0.004 | 0.890 | 0.599 - 1.324 | 0.567 |
Diarhoea <50 | 0.660 | 0.373 - 1.168 | 0.153 | |||
Dyspnea <50 | 1.095 | 0.803 - 1.491 | 0.567 | |||
Patient characteristics
| ||||||
Age | 1.011 | 0.979 - 1.044 | 0.497 | 1.085 | 1.023 - 1.152 | 0.007 |
Sex: | ||||||
- Men | 1 | 1 | ||||
- Women | 0.732 | 0.293 - 1.831 | 0.505 | 0.633 | 0.411 - 0.976 | 0.038 |
Education level: | ||||||
- Primary | 1 | |||||
- Secondary | 0.783 | 0.554 - 1.107 | 0.167 | |||
- Post secondary | 0.695 | 0.352 - 1.372 | 0.294 | |||
Stage of cancer | ||||||
- Stage I - II | 1 | 1 | ||||
- Stage III | 1.971 | 0.916 - 4.239 | 0.011 | 13.463 | 2.036 - 89.038 | 0.007 |
- Stage IV | 4.898 | 1.518 - 15.801 | <0.001 | 207.281 | 6.471 - 6639.251 | 0.003 |
Treatment before the HRQoL measurement | ||||||
- Chemotherapy only | 1 | 1 | ||||
- Chemo and radiotherapy | 0.656 | 0.388 - 1.109 | 0.115 | 0.635 | 0.366 - 1.103 | 0.107 |
- Surgery alone or surgery and radiotherapy or chemotherapy | 0.229 | 0.152 - 0.345 | <0.001 | 0.227 | 0.143 - 0.363 | <0.001 |
Interaction
| ||||||
Age*stage of cancer | 0.973 | 0.947 - 1.000 | 0.049 | 0.959 | 0.932 - 0.987 | 0.004 |
Model with global health only
| ||||||
Bivariate analysis
|
Multivariate analysis
| |||||
Variables
|
HR
|
95% CI
|
p
|
HR
|
95% CI
|
p
|
(100 = good)
| ||||||
Global HRQoL ≥50 | 0.688 | 0.504 - 0.938 | 0.018 | 0.689 | 0.501 - 0.946 | 0.021 |
Patient characteristics
| ||||||
Age | 1.011 | 0.979 - 1.044 | 0.497 | 1.083 | 1.022 - 1.147 | 0.007 |
Sex: | ||||||
- Men | 1 | 1 | ||||
- Women | 0.732 | 0.293 - 1.831 | 0.505 | 0.682 | 0.452 - 1.029 | 0.068 |
Education level: | ||||||
- Primary | 1 | |||||
- Secondary | 0.783 | 0.554 - 1.107 | 0.167 | |||
- Post secondary | 0.695 | 0.352 - 1.372 | 0.294 | |||
Stage of cancer | ||||||
- Stage I - II | 1 | 1 | ||||
- Stage III | 1.971 | 0.916 - 4.239 | 0.011 | 11.982 | 1.881 - 76.310 | 0.009 |
- Stage IV | 4.898 | 1.518 - 15.801 | <0.001 | 167.961 | 5.666 - 4979.331 | 0.003 |
Treatment before the HRQoL measurement | ||||||
- Chemotherapy only | 1 | 1 | ||||
- Chemo and radiotherapy | 0.656 | 0.388 - 1.109 | 0.115 | 0.690 | 0.406 - 1.173 | 0.171 |
- Surgery alone or surgery and radiotherapy or chemotherapy | 0.229 | 0.152 - 0.345 | <0.001 | 0.239 | 0.151 - 0.377 | <0.001 |
Interaction
| ||||||
Age*stage of cancer | 0.973 | 0.947 - 1.000 | 0.049 | 0.962 | 0.935 - 0.989 | 0.007 |
Survival analysis
-
On SF-36,patients with Bodily pain (BP) scores <50, the median survival was 9 months (CI 95%: 7 – 16) compared to 35.5 (26 – 57) if scores were ≥ 50, p < 0.001;for Social functioning, those with score <50 had a median of 8 months (5 – 25) vs 25.5 (15 – 37), p = 0.01 in patients with score ≥50;for Global health <50 the median survival was 14 (8–20) vs 37 (20 – 58) if scores ≥ 50.
-
On QLQ C-30, patients with the general QoL score <50, had a median survival of 9 months (7 – 17) compared to 29.5 (9 – 45) if scores ≥ 50.